Recombinant interleukin-2 and α-2a-interferon in pre-treated advanced soft tissue sarcomas

S. Toma, G. Melioli, R. Palumbo, R. Rosso

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fourteen patients with advanced soft tissue sarcomas (STS), all pre-treated with one or more chemotherapy (CT) lines, entered an outpatient phase II study in which subcutaneous recombinant Interleukin-2 (rIL-2) and intramuscular recombinant α-2a-interferon (r-αIFN) were concomitantly administered. Both the cytokines were given for 5 days/week for 3 consecutive weeks followed by a 2 weeks period during which only r-αIFN was administered. r-αIFN was provided at a dose of 3 x 106 International Units (IU), while rIL-2 was given at a dosage of 6 x 106/m2/day IU (in 2 subcutaneous injections), starting from 2 x 106/m2/day IU in the first week and progressively increasing to 4 and 6 x 106/m2/day IU in the second and third weeks; in 4 patients the dose of 8 x 106/m2/day IU was reached. Toxicity was moderate and correlated with rIL-2 dose; main side effects included changes in liver functionality tests (14/14), ver (13/14), fatigue (13/14), nausea and vomiting (9/14). In all 11 patients evaluable for response, stable disease (SD) was observed (duration 4-43 weeks; median 9 weeks); the median survival from the starting treatment was 18 weeks (range 1052). In all treated patients, an immunological monitoring was performed: an increase in percentage (from 10 to 74%) and in absolute number (from 400 to 4.500 cells/mm3) of CD16+ lymphocytes (NK cells) was observed in the majority of cases. Our data indicate that this regimen can be administered in pre-treated and severely immunocompromised patients with minimal to moderate toxicity on ambulatory and home bases, with acceptable clinical results.

Original languageEnglish
Pages (from-to)997-1001
Number of pages5
JournalInternational Journal of Oncology
Volume2
Issue number6
Publication statusPublished - 1993

Fingerprint

Sarcoma
Interferons
Interleukin-2
Immunologic Monitoring
Immunocompromised Host
Physiologic Monitoring
Subcutaneous Injections
Natural Killer Cells
Nausea
Vomiting
Fatigue
Outpatients
Lymphocytes
Cytokines
Drug Therapy
Survival
Liver
Therapeutics

Keywords

  • r-α-interferon 2a
  • r-interleukin-2
  • soft tissue sarcomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Recombinant interleukin-2 and α-2a-interferon in pre-treated advanced soft tissue sarcomas. / Toma, S.; Melioli, G.; Palumbo, R.; Rosso, R.

In: International Journal of Oncology, Vol. 2, No. 6, 1993, p. 997-1001.

Research output: Contribution to journalArticle

@article{e627acb4135f4188a06eefaa8a46795b,
title = "Recombinant interleukin-2 and α-2a-interferon in pre-treated advanced soft tissue sarcomas",
abstract = "Fourteen patients with advanced soft tissue sarcomas (STS), all pre-treated with one or more chemotherapy (CT) lines, entered an outpatient phase II study in which subcutaneous recombinant Interleukin-2 (rIL-2) and intramuscular recombinant α-2a-interferon (r-αIFN) were concomitantly administered. Both the cytokines were given for 5 days/week for 3 consecutive weeks followed by a 2 weeks period during which only r-αIFN was administered. r-αIFN was provided at a dose of 3 x 106 International Units (IU), while rIL-2 was given at a dosage of 6 x 106/m2/day IU (in 2 subcutaneous injections), starting from 2 x 106/m2/day IU in the first week and progressively increasing to 4 and 6 x 106/m2/day IU in the second and third weeks; in 4 patients the dose of 8 x 106/m2/day IU was reached. Toxicity was moderate and correlated with rIL-2 dose; main side effects included changes in liver functionality tests (14/14), ver (13/14), fatigue (13/14), nausea and vomiting (9/14). In all 11 patients evaluable for response, stable disease (SD) was observed (duration 4-43 weeks; median 9 weeks); the median survival from the starting treatment was 18 weeks (range 1052). In all treated patients, an immunological monitoring was performed: an increase in percentage (from 10 to 74{\%}) and in absolute number (from 400 to 4.500 cells/mm3) of CD16+ lymphocytes (NK cells) was observed in the majority of cases. Our data indicate that this regimen can be administered in pre-treated and severely immunocompromised patients with minimal to moderate toxicity on ambulatory and home bases, with acceptable clinical results.",
keywords = "r-α-interferon 2a, r-interleukin-2, soft tissue sarcomas",
author = "S. Toma and G. Melioli and R. Palumbo and R. Rosso",
year = "1993",
language = "English",
volume = "2",
pages = "997--1001",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Recombinant interleukin-2 and α-2a-interferon in pre-treated advanced soft tissue sarcomas

AU - Toma, S.

AU - Melioli, G.

AU - Palumbo, R.

AU - Rosso, R.

PY - 1993

Y1 - 1993

N2 - Fourteen patients with advanced soft tissue sarcomas (STS), all pre-treated with one or more chemotherapy (CT) lines, entered an outpatient phase II study in which subcutaneous recombinant Interleukin-2 (rIL-2) and intramuscular recombinant α-2a-interferon (r-αIFN) were concomitantly administered. Both the cytokines were given for 5 days/week for 3 consecutive weeks followed by a 2 weeks period during which only r-αIFN was administered. r-αIFN was provided at a dose of 3 x 106 International Units (IU), while rIL-2 was given at a dosage of 6 x 106/m2/day IU (in 2 subcutaneous injections), starting from 2 x 106/m2/day IU in the first week and progressively increasing to 4 and 6 x 106/m2/day IU in the second and third weeks; in 4 patients the dose of 8 x 106/m2/day IU was reached. Toxicity was moderate and correlated with rIL-2 dose; main side effects included changes in liver functionality tests (14/14), ver (13/14), fatigue (13/14), nausea and vomiting (9/14). In all 11 patients evaluable for response, stable disease (SD) was observed (duration 4-43 weeks; median 9 weeks); the median survival from the starting treatment was 18 weeks (range 1052). In all treated patients, an immunological monitoring was performed: an increase in percentage (from 10 to 74%) and in absolute number (from 400 to 4.500 cells/mm3) of CD16+ lymphocytes (NK cells) was observed in the majority of cases. Our data indicate that this regimen can be administered in pre-treated and severely immunocompromised patients with minimal to moderate toxicity on ambulatory and home bases, with acceptable clinical results.

AB - Fourteen patients with advanced soft tissue sarcomas (STS), all pre-treated with one or more chemotherapy (CT) lines, entered an outpatient phase II study in which subcutaneous recombinant Interleukin-2 (rIL-2) and intramuscular recombinant α-2a-interferon (r-αIFN) were concomitantly administered. Both the cytokines were given for 5 days/week for 3 consecutive weeks followed by a 2 weeks period during which only r-αIFN was administered. r-αIFN was provided at a dose of 3 x 106 International Units (IU), while rIL-2 was given at a dosage of 6 x 106/m2/day IU (in 2 subcutaneous injections), starting from 2 x 106/m2/day IU in the first week and progressively increasing to 4 and 6 x 106/m2/day IU in the second and third weeks; in 4 patients the dose of 8 x 106/m2/day IU was reached. Toxicity was moderate and correlated with rIL-2 dose; main side effects included changes in liver functionality tests (14/14), ver (13/14), fatigue (13/14), nausea and vomiting (9/14). In all 11 patients evaluable for response, stable disease (SD) was observed (duration 4-43 weeks; median 9 weeks); the median survival from the starting treatment was 18 weeks (range 1052). In all treated patients, an immunological monitoring was performed: an increase in percentage (from 10 to 74%) and in absolute number (from 400 to 4.500 cells/mm3) of CD16+ lymphocytes (NK cells) was observed in the majority of cases. Our data indicate that this regimen can be administered in pre-treated and severely immunocompromised patients with minimal to moderate toxicity on ambulatory and home bases, with acceptable clinical results.

KW - r-α-interferon 2a

KW - r-interleukin-2

KW - soft tissue sarcomas

UR - http://www.scopus.com/inward/record.url?scp=0027245766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027245766&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027245766

VL - 2

SP - 997

EP - 1001

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -